Daclizumab high-yield process in the treatment of relapsing–remitting multiple sclerosis

by Jana Lizrova Preiningerova, Marta Vachova
Published 2017-01-01

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

by Zbyšek Pavelek, Lukáš Sobíšek, Jana Šarláková, Pavel Potužník, Marek Peterka, Ivana Štětkárová, Pavel Štourač, Jan Mareš, Pavel Hradílek, Radek Ampapa, Markéta Grünermelová, Marta Vachová, Eva Recmanová, Francesco Angelucci, Francesco Angelucci, Simona Halúsková, Martin Vališ
Published 2021-01-01

Management of multiple sclerosis patients in central European countries: current needs and potential solutions

by Thomas Berger, Monika Adamczyk-Sowa, Tünde Csépány, Franz Fazekas, Tanja Hojs Fabjan, Dana Horáková, Zsolt Illes, Eleonóra Klimová, Fritz Leutmezer, Konrad Rejdak, Csilla Rozsa, Saša Šega Jazbec, Jarmila Szilasiová, Peter Turčáni, Marta Vachová, László Vécsei, Eva Havrdová
Published 2018-02-01

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

by Thomas Berger, Monika Adamczyk-Sowa, Tünde Csépány, Franz Fazekas, Tanja Hojs Fabjan, Dana Horáková, Alenka Horvat Ledinek, Zsolt Illes, Gisela Kobelt, Saša Šega Jazbec, Eleonóra Klímová, Fritz Leutmezer, Konrad Rejdak, Csilla Rozsa, Johann Sellner, Krzysztof Selmaj, Pavel Štouracˇ, Jarmila Szilasiová, Peter Turcˇáni, Marta Vachová, Manuela Vanecková, László Vécsei, Eva Kubala Havrdová
Published 2020-12-01